AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04240483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracutaneous sterile water injections (ISWI) group
Description: ISWI consists of 4 intracutaneous injections of 0.5 ml sterile water in the lumbosacral region while patient is in a seated position. One injection given at the posterior superior iliac spine (Point 1) on both sides and second injection at 1 cm medial, and 1-2 cm inferior to the first point on both the sides (Point 2) using an insulin needle. These points overlie the area called Michaelis' rhomboid.
Study NCT04240483 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Intracutaneous dry injections (IDI) group
Description: Intracutaneous dry injections will be performed in the same manner described above, however, no sterile water or alternative solutions will be injected into the sites.
Study NCT02497833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: retinoic acid
Description: During the trial period, the participants are instructed to consume retinoic acid capsules twice daily (30 min after breakfast and supper).The retinoic acid capsules provided a total daily intake of 10 mg of retinoic acid.
Study NCT02497833 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: During the trial period, the participants are instructed to consume placebo capsules twice daily (30 min after breakfast and supper).The placebo capsules are composed of starch and pigment.
Study NCT03291457 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: For intravenous (IV) tocilizumab, the recommended dosage is 8 milligrams per kilogram (mg/kg) once every 4 weeks. For subcutaneous (SC) tocilizumab, the recommended dosage is 162 milligrams (mg) once weekly. However, because of the observational nature of the study, dosing and treatment duration is at the discretion of the physician in accordance with local clinical practice and local labeling.
Study NCT03291457 — intervention group
Intervention type: DRUG
Intervention: Glucocorticoid Agent
Description: Because of the observational nature of the study, the choice of glucocorticoid agent, as well as dosing and treatment duration, is at the discretion of the physician in accordance with local clinical practice and local labeling.
Study NCT00710203 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed dye laser
Description: One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
Study NCT00710203 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curettage
Description: A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
Study NCT00710203 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrodesiccation
Description: A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
Study NCT00710203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No treatment
Description: A fourth lesion will not be treated and will serve as a control.
Study NCT04586647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Healthy Weight; mobile behavior change program for weight loss.
Description: The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily.
Study NCT03896217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40mg for first 4 weeks and 80mg (if tolerated) thereafter up to 17 weeks
Study NCT03896217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40mg for first 4 weeks and 80mg (if tolerated) thereafter up to 17 weeks
Study NCT03282721 — intervention group
Intervention type: PROCEDURE
Intervention: precise location of commissure
Study NCT02783729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: Lemborexant 5 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
Study NCT02783729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: Lemborexant 10 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
Study NCT02783729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lemborexant-matched placebo
Description: Lemborexant-matched placebo be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
Study NCT00309075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist)
Description: Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
Study NCT01075139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention
Description: 30 minute one-on-one meeting
Study NCT01075139 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational information
Description: Educational handouts/brochures
Study NCT00810732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open
Description: Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
Study NCT00810732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine = 30 mg extended release tablets, orally administered once daily (open label arm)
Study NCT00810732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for sitaxsentan, orally administered once daily (double blind arm)
Study NCT00724464 — intervention group
Intervention type: BIOLOGICAL
Intervention: PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b)
Description: Prior to enrollment in the study, PegIntron was to be administered at a dose of 1.5 μg/kg/week subcutaneously in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
Study NCT00724464 — intervention group
Intervention type: DRUG
Intervention: Rebetol (ribavirin)
Description: Prior to enrollment in the study, Rebetol was to be administered at a dose of 800-1200 mg/day orally in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
Study NCT03119727 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FreeO2
Description: All include patients will have automatic administration of oxygen by FreeO2 up to 3 day or until weaning of oxygen adminisatrion
Study NCT01847170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation
Study NCT00524199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Description: 12 mg/kg IV infusion over five minutes at the beginning of dialysis thrice weekly.
Study NCT00524199 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline IV infusion over five minutes at the beginning of dialysis thrice weekly.
Study NCT03350100 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance
Description: Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance at baseline, 45 post-dose, 90 min post-dose and 135 min post-dose
Study NCT03350100 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance
Description: Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance at baseline, 45 post-dose, 90 min post-dose and 135 min post-dose
Study NCT04961866 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: parenteral protein 1 g/kg
Description: patients received 1 g/ kg of protein
Study NCT04961866 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral nutrition 2 g/kg
Description: Patients received 2 g/ kg of protein
Study NCT02136433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet - self exercise
Study NCT02136433 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GRASP self exercise
Study NCT02595216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profound System
Description: The Profound system is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of submental laxity
Study NCT00601484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04383119
Description: PF-04383119 200 mcg/kg IV, single dose
Study NCT00601484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo IV, single dose
Study NCT04744740 — intervention group
Intervention type: DEVICE
Intervention: in-home sleep recording
Description: in-home, nightly, zero-burden objective quantification of sleep scheduling and sleep heart rate via a mattress-top sensor (Sleepace RestOn) + ad lib quantification of blood SaO2 via a ring-based sensor (Bodimetrics Circul) + ad lib quantification of sleep and waking activity and heart rate via a wrist-worn sensor (Garmin Vivosmart 4)
Study NCT03324880 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhPTH (1-84)
Description: rhPTH (1-84) SC injection.
Study NCT03324880 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD SC injection.
Study NCT01036022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1399686
Description: Each dose level of GSK1399686 will be subsequently tested in a cohort of approximately 20 patients, who will be randomized in a 3:1:1 ratio to receive GSK1399686 (once daily over 4 weeks, followed by 2 weeks dosing with placebo), placebo, or ASACOL (t.i.d. for 6 weeks), respectively.
Study NCT01257711 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux-en-Y or Billroth II
Description: Roux-en-Y had fewer problems related to reflux of bile but a higher incidence of stasis in the Roux limb resulting in longer hospital stay. Some surgeon avoids doing Roux-en-Y is a triad of post operative symptoms including abdominal pain, vomiting and nausea called Roux-en-Y loop syndrome. Billroth II reconstruction is a simpler operation with only one anastomosis and faster operating time. This has implications while managing gastric cancer patients who may be malnourished and a simpler procedure may have lesser risk of complications and yield better outcomes. Billroth II has increased reflux associated problem like esophagitis and gastritis, risk of afferent loop and dumping syndrome. Long term nutritional outcomes are similar for both procedures.
Study NCT03991832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is a drug that blocks a protein called poly (ADP-ribose) polymerase (PARP). PARP is important in the growth and spread of cancer cells. Because of this, blocking PARP from working is expected to stop the growth of or shrink cancer cells.
Study NCT02783729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lemborexant-matched placebo
Description: Lemborexant-matched placebo be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
Study NCT02783729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem tartrate
Description: Zolpidem tartrate extended release 6.25 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
Study NCT02783729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem-matched placebo
Description: Zolpidem-matched placebo will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
Study NCT03300570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolcanatide
Description: Given PO
Study NCT02783729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zolpidem-matched placebo
Description: Zolpidem-matched placebo will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
Study NCT03300570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03300570 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03300570 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT03300570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03300570 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02807428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AYX1 Injection 660 mg/6 mL
Description: 6 mL solution for intrathecal injection with 660 mg of AYX1 (Brivoligide)
Study NCT02807428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection 6 mL
Description: 6 mL solution for intrathecal injection; vehicle formulation designed to mimic AYX1 Injection (with no active drug)
Study NCT00829335 — intervention group
Intervention type: PROCEDURE
Intervention: IOUS-GUIDED INTRAHEPATIC VESSEL COMPRESSION
Description: Using the IOUS, the tumor and the level targeted for compression are identified. Than, under the IOUS guidance, the surgeon compresses bilaterally the liver at the targeted position resulting in the compression of the portal pedicle feeding the tumor previously identified. This maneuver is constantly monitored in real-time just using the same microconvex probe, and it is maintained until the surface of the targeted liver area begins to discolor, at that time the first assistant marks the discolored area with the electrocautery, and the compression is released. Once the area is demarcated, liver dissection is started under intermittent Pringle's maneuver.
Study NCT04588935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol; Perindopril;
Description: based on the results of the patient study, different drug therapy regimens for cardiovascular complications during chemotherapy will be proposed
Study NCT03217435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal epithelial allograft
Description: A living-related donor's epithelial flap, equal in area to the recipient's diseased cornea bed, will be created using femtosecond laser technology. This corneal epithelial allograft is then ready for transplantation on the recipient's disease eye, following removal of the recipient's scarred and diseased epithelium.
Study NCT03217435 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limbal conjunctival allograft
Description: A 3- to 5- clock hour limbal-conjunctival allograft will be obtained from the living-related eye. This is then ready for transplantation on the recipient's disease eye following removal of the recipient's scarred and diseased epithelium.
Study NCT03991832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a drug that works by stopping a protein called Programmed Cell Death Ligand 1 (PD-L1) from working. PD-L1 is a protein that is thought to prevent the immune system (the body's defense against diseases) from killing cancer cells. Stopping PD-L1 from working is expected to allow the immune system to once again prevent or slow down cancer growth.
Study NCT03217435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser
Description: A commercial femtosecond laser to create a particular shaped graft for transplantation
Study NCT03217435 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diamond knife
Description: A diamond knife to create a particular shaped limbal graft for transplantation
Study NCT04305002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Injections, 2 mg once weekly for 18 months
Study NCT04305002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injections, once weekly for 18 months
Study NCT04189263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate restricted dietary intervention
Description: Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day)
Study NCT04189263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard of care aromatase inhibitors
Description: standard of care aromatase inhibitors
Study NCT04189263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care aromatase inhibitors
Description: standard of care aromatase inhibitors
Study NCT02810093 — intervention group
Intervention type: OTHER
Intervention: retrospective medical records analyze
Description: Ten thousand medical records (between years 2000 and 2016) will be analyzed
Study NCT01481545 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be administered at the total dose of 45 Gy, given with five weekly fractions over a period of 5 weeks. The daily fraction dose will be 1.8 Gy
Study NCT01481545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
Study NCT01481545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: 2.5 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1) , an additional 2 cycles of chemotherapy will be given after radiation therapy)
Study NCT01481545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofolinic acid
Description: 250 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
Study NCT01481545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 800 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
Study NCT01481545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: will be given by intravenous infusion at the dose of 5 mg/kg concurrent with chemotherapy and radiotherapy every 2 weeks for 4 cycles from -14 days to start chemo-radiotherapy (classical schedule) or 4 days before the concurrent administration of chemotherapy and radiation therapy for 2 cycles if the number of TRG1 was not reached in the first stage (statistical design) with the classical schedule (for patients with resectable organ metastases (M1), one additional administration of bevacizumab will be given after radiation therapy)
Study NCT02503683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-AAT
Description: Single or multiple doses of ALN-AAT by subcutaneous (sc) injection
Study NCT02503683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: calculated volume to match active comparator
Study NCT04021186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention of hyperglycemia
Description: Bigger focus on postoperative blood-glucose levels in order to reduce incidents of hyperglycemia and other surgical complications.
Study NCT01919970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: This condition involves 12 weekly CBT sessions.
Study NCT01919970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
Study NCT02815995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).
Study NCT02815995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
Study NCT00990340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-jet® containing TevTropin®
Description: Needle-free delivery method for 14 days before cross-over to other arm
Study NCT00990340 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TevTropin® needle-syringe injection method
Description: comparison of delivery methods for 14 days before cross-over to other arm
Study NCT04108195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive daratumumab.
Study NCT04108195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Participants will receive talquetamab.